Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9683909 | 0.81 | SLC6A4 (0.40) | SLC6A4SLC6A2KMT2AALDH1A1 | |
| SCHEMBL10260948 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3TDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9682487 | 0.79 | SLC6A4 (0.39) | SLC6A4SLC6A2KMT2AALDH1A1LMNA | |
| SCHEMBL1812729 | 0.78 | SLC6A4 (0.36) | SLC6A4CYP2D6 | |
| SCHEMBL20012540 | 0.77 | CARM1 (0.47) | SLC6A4SLC6A2SLC6A3TDP1ALDH1A1 | |
| SCHEMBL20068827 | 0.76 | SSTR4 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20176375 | 0.76 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10035281 | 0.75 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3ALDH1A1GLA | |
| SCHEMBL10608615 | 0.74 | MCHR1 (0.59) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20158870 | 0.73 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A4 3586/4885SLC6A2 4053/4885SLC6A3 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.